[1]胡均立,潘赐明,石行,等.1990—2021年中国10～24岁年龄段人群痛风的疾病负担和风险因素分析及2022—2035年中国10～24岁年龄段人群痛风的疾病负担预测[J].中医正骨,2025,37(06):1-7,18.
　HU Junli,PAN Ciming,SHI Hang,et al.Analyzing the disease burden and risk factors of gout during 1990—2021 and projecting the future burden during 2022—2035 in the Chinese 10-24-year-olds[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2025,37(06):1-7,18.
点击复制

1990—2021年中国10～24岁年龄段人群痛风的疾病负担和风险因素分析及2022—2035年中国10～24岁年龄段人群痛风的疾病负担预测()

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第37卷
期数:
2025年06期
页码:
1-7,18
栏目:
数据库研究
出版日期:
2025-06-20

文章信息/Info

Title:
Analyzing the disease burden and risk factors of gout during 1990—2021 and projecting the future burden during 2022—2035 in the Chinese 10-24-year-olds
作者:
胡均立1; 潘赐明2; 石行3; 李仪杰4
1.湖北航天医院,湖北 孝感 432000; 2.昆明呈贡汇贤中医医院,云南 昆明 650500; 3.昭通市第三人民医院,云南 昭通 657100; 4.潍坊市精神卫生中心,山东 潍坊 261000
Author(s):
HU Junli1; PAN Ciming2; SHI Hang3; LI Yijie4
1.Hubei Aerospace Hospital,Xiaogan 432000,Hubei,China 2.Huixian Hospital of Traditional Chinese Medicine in Chenggong District,Kunming 650500,Yunnan,China 3.Zhaotong Third People's Hospital,Zhaotong 657100,Yunnan,China 4.Weifang Mental Health Center,Weifang 261000,Shandong,China
关键词:
痛风;  中国;  青少年;  年轻人;  疾病负担;  患病率;  发病率;  伤残调整寿命年
Keywords:
gout;  China;  adolescent;  young adult;  disease burden;  prevalence;  incidence;  disability-adjusted life years
摘要:
目的:分析1990—2021年中国10～24岁年龄段人群痛风的疾病负担和风险因素,预测2022—2035年中国10～24岁年龄段人群痛风的疾病负担。方法:从全球疾病负担(global burden of disease,GBD)公共数据库获取中国和全球10～24岁年龄段人群痛风的疾病负担数据及中国10～24岁年龄段人群痛风的风险因素数据,采用JD_GBDR_V2.36软件中的“表格结果”功能比较分析2021年中国和全球10～24岁年龄段人群痛风的疾病负担,比较分析1990年和2021年中国10～24岁不同年龄段人群痛风的疾病负担,分析1990—2021年中国不同性别10～24岁年龄段人群痛风的疾病负担变化趋势; 采用“Risk分析”功能分析1990—2021年中国10～24岁年龄段人群痛风的风险因素; 采用“预测分析”功能预测2022—2035年中国10～24岁年龄段人群痛风的疾病负担。结果:①2021年中国和全球10～24岁年龄段人群痛风的疾病负担比较分析结果。2021年中国10～24岁年龄段人群痛风的患病人数、发病人数和伤残调整寿命年(disability-adjusted life year,DALY)分别占全球10～24岁年龄段人群的 18.63%、19.51%和18.70%。2021年中国10～24岁年龄段人群痛风的患病率、发病率、DALY率均高于全球10～24岁年龄段人群。②1990年和2021年中国10～24岁不同年龄段人群痛风的疾病负担比较分析结果。与1990年比较,2021年中国10～24岁年龄段人群痛风的患病人数下降36.38%[95%UI(33.05%,39.47%)],患病率年度平均百分比变化(estimated annual percentage change,EAPC)为0.72[95%UI(0.26,1.19)]; 发病人数下降35.49%[95%UI(32.96%,38.05%)],发病率EAPC为0.78[95%UI(0.33,1.24)]; DALY下降36.38%[95%UI(33.05%,39.47%)],DALY率EAPC为0.72[95%UI(0.26,1.19)]。15～19岁年龄段人群痛风的患病人数下降35.29%[95%UI(26.19%,40.33%)],患病率EAPC为0.33[95%UI(0.31,0.35)]; 发病人数下降35.37%[95%UI(26.39%,40.46%)],发病率EAPC为0.33[95%UI(0.31,0.34)]; DALY下降35.29%[95%UI(26.19%,40.33%)],DALY率EAPC为0.33[95%UI(0.32,0.35)]。20～24岁年龄段人群痛风的患病人数下降36.49%[95%UI(33.20%,39.74%)],患病率EAPC为0.54[95%UI(0.50,0.59)]; 发病人数下降35.51%[95%UI(33.10%,38.19%)],发病率EAPC为0.63[95%UI(0.57,0.69)]; DALY下降36.49%[95%UI(33.20%,39.74%)],DALY率EAPC为0.54[95%UI(0.49,0.59)]。③1990—2021年中国不同性别10～24岁年龄段人群痛风的疾病负担变化趋势分析结果。1990—2021年中国10～24岁年龄段人群、男性10～24岁年龄段人群、女性10～24岁年龄段人群痛风的患病人数、患病率、发病人数、发病率、DALY、DALY率均呈先下降后上升再下降的变化趋势,且男性10～24岁年龄段人群的患病人数、患病率、发病人数、发病率、DALY、DALY率均高于女性10～24岁年龄段人群。④1990—2021年中国10～24岁年龄段人群痛风的DALY风险因素分析结果。中国10～24岁年龄段人群痛风的DALY风险因素包括代谢异常、体质量指数高和肾功能障碍。1990—2021年,体质量指数高和代谢异常导致的DALY占比呈上升趋势,肾功能障碍导致的DALY占比呈下降趋势。⑤2022—2035年中国10～24岁年龄段人群痛风疾病负担预测结果。2022—2035年,中国男性10～24岁年龄段人群痛风患病率呈下降趋势,发病率呈先上升后下降趋势; 女性痛风患病率和发病率均呈先小幅下降后小幅上升趋势; 痛风DALY率均保持基本不变。结论:1990—2021年中国10～24岁年龄段人群痛风的疾病负担较为严重,代谢异常、体质量指数高和肾功能障碍是该年龄段人群痛风的主要风险因素; 2022—2035年中国10～24岁年龄段人群仍将面临较为严重的痛风疾病负担,应重视该年龄段人群痛风的防治工作。
Abstract:
Objective:To analyze the disease burden and risk factors of gout among the Chinese 10-24-year-olds during 1990—2021,and to project the future gout-related disease burden for the period of 2022—2035.Methods:Data on the disease burden of gout in the Chinese and global individuals aged 10-24 years,and the risk factors for gout within this age group in China,were retrieved and extracted from the global burden of disease(GBD)study public database.After that,the“Table Results”function within the JD_GBDR_V2.36 software was employed to compare and analyze the disease burden of gout among the Chinese and global 10-24-year-olds in 2021,and the di-sease burden of gout across different age subgroups within the Chinese 10-24 cohort in 1990 and 2021,meanwhile,the temporal trends in the disease burden of gout among the Chinese 10-24-year-olds from 1990 to 2021 were analyzed by gender.Furthermore,the risk factors for gout among the Chinese 10-24-year-olds during 1990—2021 were analyzed using the“Risk Analysis”function,and the disease burden of gout in this individuals for the period of 2022—2035 was projected using the“Projection Analysis”function.Results:①Disease burden of gout among the 10-24-year-olds in 2021:China versus worldwide.In 2021,the number of prevalent cases and incident cases,and the disability-adjusted life years(DALYs)of gout among the Chinese 10-24-year-olds accounted for 18.63%,19.51%,and 18.70% of the global totals in this age group,respectively,and the prevalence,incidence,and DALY rates of gout were higher in this Chinese population compared to the corresponding global ones.②Disease burden of gout across different age subgroups within the 10-24-year-olds in China:1990 versus 2021.Compared with that in 1990,the Chinese 10-24-year-olds in 2021 exhibited 36.38%(95%UI(33.05%,39.47%)),35.49%(95%UI(32.96%,38.05%))and 36.38%(95%UI(33.05%,39.47%))reductions in gout prevalent cases,incident cases,and DALYs,respectively,with the estimated annual percentage change(EAPC)of 0.72(95%UI(0.26,1.19)),0.78(95%UI(0.33,1.24)),and 0.72(95%UI(0.26,1.19))in prevalence rate,incidence rate,and DALY rate,respectively.Among the 15-19-year-olds,the gout prevalent cases,incident cases,and DALYs decreased by 35.29%(95%UI(26.19%,40.33%)),35.37%(95%UI(26.39%,40.46%)),and 35.29%(95%UI(26.19%,40.33%)),respectively,with the EAPC of 0.33(95%UI(0.31,0.35)),0.33(95%UI(0.31,0.34)),and 0.33(95%UI(0.32,0.35))in prevalence rate,incidence rate,and DALY rate,respectively.Among the 20-24-year-olds,the gout prevalent cases,incident cases,and DALYs decreased by 36.49%(95%UI(33.20%,39.74%)),35.51%(95%UI(33.10%,38.19%)),and 36.49%(95%UI(33.20%,39.74%)),respectively,with the EAPC of 0.54(95%UI(0.50,0.59)),0.63(95%UI(0.57,0.69)),and 0.54(95%UI(0.49,0.59))in prevalence rate,incidence rate,and DALY rate,respectively.③Temporal trends in the disease burden of gout among 10-24-year-olds in china by gender:1990—2021.During 1990—2021,the gout burden metrics,including prevalent cases,prevalence rate,incident cases,incidence rate,DALYs,and DALY rate,presented a biphasic trajectory of initial decline followed by resurgence and subsequent re-decline among the Chinese 10-24-year-olds,as well as the male and female 10-24-year-olds.Notably,the six metrics in the males consistently exceeded the corresponding values in females within this age group.④Risk factors for gout-related DALYs among 10-24-year-olds in China:1990—2021.Among the Chinese 10-24-year-olds,the key risk factors for gout-related DALYs include metabolic abnormalities,high body mass index(BMI),and renal dysfunction.From 1990 to 2021,the proportion of DALYs attributable to high BMI and metabolic abnormalities demonstrated an increasing trajectory,whereas the proportion attributable to renal dysfunction exhibited a declining trajectory.⑤Projection of disease burden of gout among 10-24-year-olds in China:2022—2035.During 2022—2035,the gout prevalence rate presented a declining trajectory among the male 10-24-year-olds,while a modest biphasic trajectory of minor initial decline followed by marginal increase among the females; and the incidence rate showed a biphasic trajectory of initial ascend followed by reduction among the male 10-24-year-olds,while a modest biphasic trajectory of minor initial decline followed by marginal increase among the females; whereas,the DALY rate remain essentially stable among the male and female 10-24-year-olds.Conclusion:During 1990—2021,the Chinese 10-24-year-olds carried a substantial gout-related disease burden,with metabolic abnormalities,high BMI,and renal dysfunction constituting primary risk factors,they are still projected to face a substantial gout-related disease burden during 2022—2035,targeted interventions for prevention and management in this population are warranted.

参考文献/References:

[1] 世界中医药学会联合会.国际中医临床实践指南 痛风(2024-03-14)[J].世界中医药,2024,19(9):1223-1229.
[2] DO H,CHOE K,KIM M J,et al.Sex differences in clinical features in gout:a nationwide retrospective cohort study[J].J Clin Med,2024,13(23):7095.
[3] YAN Y,BAI Y,WANG J,et al.Cardiovascular outcomes of urate-lowering therapies in patients with gout or hyperuricemia:a network meta-analysis[J/OL].Expert Opin Drug Saf,2024[2024-12-17].https://pubmed.ncbi.nlm.nih.gov/39541111/.
[4] XI J,CHENG X,LIU J.Causal relationship between gout and liver cancer:a mendelian randomization and transcriptome analysis[J].Medicine(Baltimore),2024,103(45):e40299.
[5] CHONG B,KONG G,SHANKAR K,et al.The global syndemic of metabolic diseases in the young adult population:a consortium of trends and projections from the Global Burden of Disease 2000-2019[J].Metabolism,2023,141:155402.
[6] WHITE-KONING M,WRIGHT D F B,HUGHES D A,et al.Relative forgiveness of different allopurinol implementation patterns in people with gout and their impact on clinical outcomes:a simulation study[J].Clin Pharmacokinet,2025,64(1):93-105.
[7] 王荣,薛晓梅,贺玉伟,等.痛风急性发作危险因素分析[J].山东医药,2023,63(24):30-33.
[8] 兰清云.大学生高尿酸血症及痛风的现状调查研究[J].全科口腔医学电子杂志,2018,5(34):117.
[9] 徐艳玲,杜献丽,杜敏,等.痛风性关节炎的延续护理[J].中医正骨,2020,32(5):74-76.
[10] 吕彬彬.大学生痛风管理的个案护理[J].医学食疗与健康,2020,18(2):113.
[11] LI Q H,ZOU Y W,LIAN S Y,et al.Sugar-sweetened beve-rage consumption is associated with more obesity and higher serum uric acid in Chinese male gout patients with early onset[J].Front Nutr,2022,9:916811.
[12] 黄锦坚,王雨,林志健,等.基于美国国家健康和营养检查调查数据库的痛风病证素研究[J].世界中医药,2024,19(13):1889-1895.
[13] 戚跃,张婷,王俊.学生身体质量指数与体适能的相关性[J].淮北师范大学学报(自然科学版),2024,45(3):73-77.
[14] 姚尊一萍.大学生身体质量指数、身体不满意与焦虑的关系研究[J].心理月刊,2024,19(20):39-43.
[15] 黄仁坤,卢玠桦,盛关云,等.身体质量指数与椎间盘突出的两样本孟德尔随机化研究[J].现代预防医学,2024,51(15):2875-2880.
[16] 尤琦琦.基于健康高危险性理论的大学生身体质量指数与高血压关系研究[D].武汉:华中科技大学,2023.

相似文献/References:

[1]向黎黎,熊辉,陆小龙,等.中药治疗痛风用药规律的文献研究[J].中医正骨,2015,27(12):46.
　XIANG Lili,XIONG Hui,LU Xiaolong,et al.Literature research on medication rule of Traditional Chinese Medicine for treatment of gout[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(06):46.
[2]李益亮,孙绍裘.孙达武教授运用口服宣痹通络膏治疗 痛风湿热痹阻证的经验[J].中医正骨,2016,28(02):75.
[3]黄哲康,袁慧敏,刘晋闽.手术治疗四肢多发巨大痛风石[J].中医正骨,2018,30(01):70.
[4]钟伟兴,温干军,李义凯.中医治疗痛风临床和科研中存在的问题[J].中医正骨,2020,32(07):30.
[5]刘振江,李根和,王敬轩,等.痛风骨侵蚀致髌骨骨折术后内固定失效1例[J].中医正骨,2024,36(11):78.

备注/Memo

备注/Memo:
基金项目:云南省南药可持续利用研究重点实验室开放课题(202105AG070012XS2242)
通讯作者:潘赐明 E-mail:gspcm@foxmail.com
更新日期/Last Update: 1900-01-01